Cyclo Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cyclo Therapeutics generated cash of -$16,185,026, which is less than the previous year. Cash used in financing activities reached the amount of $23,890,620 last year. Net change in cash is therefore $7,703,174.
Cash Flow
| 2014 | -631.16K | -173.88K | 2.91M |
|---|---|---|---|
| 2015 | -1.98M | -418.53K | 1.87M |
| 2016 | -2.95M | 942.93K | 1.12M |
| 2017 | -3.06M | 32.20K | 3.34M |
| 2018 | -3.18M | 32.94K | 4.10M |
| 2019 | -6.58M | 36.13K | 7.11M |
| 2020 | -8.54M | -14.04K | 18.61M |
| 2021 | -15.00M | 14.82K | 18.75M |
| 2022 | -15.11M | 38.17K | 6.77K |
| 2023 | -16.18M | -2.42K | 23.89M |
CYTH Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.54M | 16.61M | 12.84M | 2.78M | 2.21M | 1.27M | 960.19K | 1.84M | 2.38M | 268.51K |
Operating activities | ||||||||||
Net income | -20.05M | -15.45M | -14.28M | -8.94M | -7.53M | -4.25M | -3.83M | -4.22M | -2.55M | -592.68K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 19.27K | 19.48K | 16.82K | 12.76K | 5.68K | 10.12K | 9.27K | 107.09K | 169.03K | 152.44K |
Stock-based compensation expense | 736.91K | 513.56K | 470.87K | 271.30K | 436.69K | 0 | 118.68K | 121.46K | 74.6K | 160.2K |
| Deferred income tax benefit | 736.91K | 513.56K | 470.87K | 271.30K | 436.69K | 0 | 118.68K | 121.46K | 74.6K | 160.2K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -67.38K | 427.85K | -444.02K | 72.41K | -63.38K | -23.18K | 32.80K | -34.03K | 25.34K | 18.30K |
Inventories | -52.78K | -27.05K | 10.47K | 4.72K | 160.63K | 42.54K | 20.67K | 112.72K | -45.55K | -327.72K |
Accounts payable | 3.24M | -200.38K | -794.42K | 39.80K | 387.98K | 97.26K | 593.42K | 87.70K | 78.81K | -38.48K |
Cash generated by operating activities | -16.18M | -15.11M | -15.00M | -8.54M | -6.58M | -3.18M | -3.06M | -2.95M | -1.98M | -631.16K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.42K | -15.08K | -22.5K | -53.12K | -1.32K | -2.95K | -6.85K | -9.34K | -419.23K | -173.88K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 4.65K | 924.69K | 700 | 0 |
Cash generated by investing activities | -2.42K | 38.17K | 14.82K | -14.04K | 36.13K | 32.94K | 32.20K | 942.93K | -418.53K | -173.88K |
Financing activities | ||||||||||
Common Stock Issued | 9.73M | 159.51K | 18.76M | 18.45M | 6.98M | 4.10M | 3.34M | 1.88M | 1.91M | 3.02M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 6.77K | -6.77K | -158.52K | 0 | 0 | 0 | -754.03K | -40.46K | -57.27K |
Cash used in financing activities | 23.89M | 6.77K | 18.75M | 18.61M | 7.11M | 4.10M | 3.34M | 1.12M | 1.87M | 2.91M |
Net Change In Cash | 7.70M | -15.06M | 3.76M | 10.06M | 566.30K | 946.43K | 310.77K | -882.03K | -537.82K | 2.11M |
Cash at end of period | 9.24M | 1.54M | 16.61M | 12.84M | 2.78M | 2.21M | 1.27M | 960.19K | 1.84M | 2.38M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |